Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Print this page

A Basket Trial of Pembrolizumab in Patients with Advanced Solid Tumors and Genomic Instability (multi-center)

To evaluate the response rate of pembrolizumab in patients with evidence of genomic instability classified as follows: 1) All solid tumors with POLE and POLD1 mutations 2) All solid tumors with BRCA1/2 mutations

Protocol Number: 051709
Phase: Phase II
Applicable Disease Sites: Any Site
Drugs Involved: Pembrolizumab (MK-3475)
Principal Investigator: Eugenia Girda Assistant Professor GYN
Scope: Local
Therapies Involved: Immunotherapy
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
  • NYU Langone Medical Center (Tisch Hospital)
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.